TransMedics GroupTMDX
Recorded

TransMedics Group 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 7 minParticipants16

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to TransMedics' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Hannah Jeffrey from the Gilmartin Group for a few introductory comments.

Hannah JeffreyVP

Thanks, operator. Good afternoon, and welcome to TransMedics' third quarter 2026 earnings call. I am joined by our President and CEO, Waleed Hassanein, and our CFO, Fernando Araujo. During this call, we will make forward-looking statements, which are based on how we see things today and are subject to various assumptions. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. Our conference call remarks will also include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures, along with information regarding our use of forward-looking statements, can be found in today's press release and in the presentation slides available on our website. With that, I will hand the call over to Waleed.

Waleed HassaneinPresident and CEO

Thank you, Hannah. Good afternoon, everyone, and thank you for joining TransMedics' third quarter 2026 earnings call. I am delighted to be joined today by Fernando Araujo, our new Chief Financial Officer, who will review our third quarter financial results in detail later on this call. TransMedics has built one-of-a-kind transplant business founded on five foundational assets that are extremely difficult to replicate. At the core is our transformative OCS technology platform, amplified by our clinical organ procurement and donor screening services, and enabled by our vertically integrated logistics network and NOP digital assets. Together, they form a single integrated platform with one purpose: to increase the number of organ transplants and improve outcomes for patients worldwide. Our goal is crystal clear: to be the trusted partner to every stakeholder in organ transplantation committed to growing transplant volumes, maximizing efficiency, and improving post-transplant clinical outcomes.

Waleed HassaneinPresident and CEO

We are very proud of what we have built, but we are not standing still. We firmly believe our best innings are still ahead, and this conviction is why we continue to invest in innovation-driven growth across technology, services, and digital transformation of the transplant ecosystem. I will update you on the progress of these initiatives shortly. Turning to 3Q results. The third quarter of 2026 was the strongest in TransMedics' history for both revenue and case volume. Third quarter highlights include total revenue of approximately $203 million, up approximately 41% year-over-year. Transplant product revenue of $113 million, up approximately 29% year-over-year. And transplant service revenue of roughly $79 million, up approximately 44% year-over-year.

Waleed HassaneinPresident and CEO

Despite typical third quarter seasonality, OCS liver and heart case volume grew both year-over-year and sequentially, modestly surpassing the all-time high levels we set in the second quarter of 2026. As our near and mid-term growth initiatives begin contributing to case volumes, we fully expect product revenue growth to accelerate further and converge with our service growth rates. TransMedics Transplant Logistics generated approximately $41 million in revenue, up approximately 50% year-over-year. We supported approximately 86% of NOP missions requiring air transport using our own fleet. This is consistent with our second quarter performance and meeting our steady state goal of managing more than 80% of our NOP missions. We ended the quarter with approximately $493 million in cash and cash equivalents.

Waleed HassaneinPresident and CEO

Looking at our third quarter results, we are especially proud of our record revenue performance, which was driven primarily by market share gains in liver and heart and strong clinical service revenue. Again, we delivered this growth despite typical third quarter seasonality and lower overall U.S. deceased donor volume that was down 6% in 3Q 2026. Importantly, we achieved these results with no incremental contribution yet from ENHANCE Part B or DENOVO. We also drove product service margin expansion and generated approximately $20 million in cash. Beyond this strong financial performance, we also successfully advanced several of our near and mid-term growth initiatives. Let me start with the heart, where we are working to further expand OCS adoption in the existing indication and expand into new indications in the United States.

Waleed HassaneinPresident and CEO

Our ENHANCE Heart Part A program was designed to demonstrate the safety and effectiveness of our OCS Heart 2.0 enhancements and a new proprietary perfusion solution within our current OCS Heart indications, which covers extended criteria DBD and DCD donor hearts. We completed enrollment of 175 patients in September, and in October, FDA approved a continued access protocol, or CAP, allowing us to enroll an additional 90 patients in the CAP protocol. We expect CAP enrollment to begin in late fourth quarter 2026 or early first quarter 2027. ENHANCE Heart Part B is designed to open an entirely new indication for TransMedics, focusing on DBD donor hearts preserved within roughly four hours of preservation. This segment represented approximately 2,200 heart transplanted in 2025. In late October, the FDA approved our IDE protocol amendment to include the TransMedics Controlled Hypothermic Organ Preservation System, or CHOPS, as the control arm.

Waleed HassaneinPresident and CEO

That gives us two shots at goal in this segment, OCS Heart and the TransMedics CHOPS, with the potential to offer the market two distinct options at different price points. Part B is designed to enroll approximately 600 patients, 400 on OCS and 200 on CHOPS. Participating centers are now completing their internal IRB processes, and we expect Part B to be a major catalyst for our heart business beginning in the first quarter of 2027. Next is expanding adoption of OCS in the lung transplant market, which we believe could be a sleeping giant for TransMedics business. Our DENOVO Lung program leverages our Gen 2.0 OCS Lung enhancement, and again, a new proprietary perfusion solution to generate data that we believe will catalyze a large untapped U.S. lung transplant market of approximately 3,500 transplants annually, the vast majority of which use no form of machine perfusion today.

Waleed HassaneinPresident and CEO

In late October, FDA also approved our IDE protocol amendment to include CHOPS as the DENOVO control arm. Together, OCS Lung and TransMedics CHOPS represent a significant opportunity to transform this market. DENOVO is designed to enroll approximately 450 patients, 300 on OCS and 150 on CHOPS. As with ENHANCE, centers are completing their IRB processes, and we expect DENOVO to be a major catalyst for our lung business beginning in the first quarter of 2027. Taken together, ENHANCE Heart and DENOVO Lung give us access to conservatively estimated 2,000-5,000 incremental U.S. heart and lung cases annually, materially expanding our U.S. addressable market. In addition, data from these programs will also help catalyze heart and lung transplant adoption internationally. Beyond our clinical programs, we continue to make progress expanding OCS NOP and transplant logistics in Europe.

Waleed HassaneinPresident and CEO

Tamer and our European commercial team have made significant strides and are preparing to launch OCS NOP in Italy, Netherlands, and Belgium in H1 2027. They are also in active discussion with several additional European countries about expansion beyond these initial markets. This groundwork supported strong European performance in the third quarter of 2026. Importantly, I am delighted to report that in October, our PAD Aviation business won TransMedics' first European transplant logistics tender in Italy's Emilia-Romagna region. This is a strategic first step towards our vision of a dedicated pan-European transplant logistics network, modeled on what we have built in the United States. With significant need and established budgets for transplant logistics across Europe, we see logistics as a powerful entry point for OCS NOP in the many countries where we are actively engaged.

Waleed HassaneinPresident and CEO

We expect OCS NOP and European transplant logistics together to become another growth catalyst for TransMedics in 2027. Meanwhile, we remain laser-focused on OCS Kidney, our entry into the largest transplant market segment, with what we believe will be the first portable normothermic oxygenated kidney perfusion system. In the U.S., approximately 21,000 deceased donor kidneys are transplanted each year, and approximately 9,000 more go unused, in part due to prolonged ischemic time. This is the single largest addressable transplant segment available to us in the U.S. and globally. We are building OCS Kidney on our next-gen 3.0 platform, which is designed to add meaningful scale and operating leverage across our business. OCS Kidney development is progressing well, and we remain on track for the first in-man clinical experience in the second half of 2027.

Waleed HassaneinPresident and CEO

From there, we expect OCS Kidney to become another major growth catalyst for TransMedics beginning in late 2027 and into 2028. Finally, turning to the U.S. transplant and OPO modernization initiative led by HHS and CMS. On October 30th, CMS released its final rule on OPO certification. The key highlights were: CMS affirmed the outcome-based three-tier performance framework, and that it will be applied on a DSA-by-DSA basis. CMS allowed for OPOs for the first time to hold multiple DSAs, with CMS formalizing when a DSA opens for competition and how successor OPOs are selected. In addition, CMS removed the historical requirements that an organization must have operated as an OPO between 2002 and 2005 to qualify to become an OPO. This opens the door for new entities to become OPOs. However, CMS deferred finalization of a pathway for new OPOs to further rule-making process.

Waleed HassaneinPresident and CEO

CMS also stipulated that designation period may be shortened or extended, and CMS may directly assign a DSA when time doesn't allow for a full competitive process. Bottom line is, based on our review, we see nothing in the final rule that would prevent TransMedics business from progressing as planned, as we do it every day. Meanwhile, we are actively collaborating with approximately 20 OPOs across the U.S. to help them improve donor organ utilization and meet CMS performance tier metrics. We remain committed to supporting every OPO in meeting or exceeding these metrics, because doing so ultimately means saving more American lives. Turning to guidance. Given our strong year-to-date performance and balanced against the timing of our new program contributing to early 2027 rather than the fourth quarter, we are raising our full year 2026 revenue guidance to a range of $764 million-$774 million, inclusive of approximately $14 million from PAD Aviation, representing growth of approximately 26%-28% over 2025.

Waleed HassaneinPresident and CEO

Importantly, this range assumes no meaningful incremental revenue from ENHANCE Part B or DENOVO in the fourth quarter. Fernando will detail the guidance update in his section of today's call. In summary, over the past four years, TransMedics has consistently turned strategic investments into both rapid top-line growth and strong bottom-line performance. We are a growth company at our core, leading bold, far-reaching innovations across our OCS technology platform, our clinical and logistics services, and the digital transformation of the entire transplant ecosystem.

Waleed HassaneinPresident and CEO

The progress we made on our growth initiatives in 2026 gives us the confidence that our best years are still ahead. TransMedics is once again well-positioned to lead the next wave of innovation in organ transplant worldwide in 2027 and beyond. With that, I will turn the call over to Fernando to review our third quarter financial results in detail.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day